Avid Logo June 2022.jpg
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
02 juil. 2024 16h05 HE | Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...
22157.jpg
Gene Therapy R&D Market Report 2024-2034 - Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments and a Promising Pipeline Reshaping Medicine's Future
01 juil. 2024 10h10 HE | Research and Markets
Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. World revenue for Gene Therapy R&D Market is...
SentiBioLogo.jpg
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
01 juil. 2024 08h05 HE | Senti Biosciences, Inc.
The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202.
Avid Logo June 2022.jpg
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
01 juil. 2024 07h00 HE | Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
27 juin 2024 06h30 HE | Medigene AG
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
22157.jpg
Global Cell and Gene Therapy CRO Market Research 2024-2035: Over 105 CROs Drive Innovations with 80% Ensuring Comprehensive Support from R&D to Clinical Trials
26 juin 2024 06h37 HE | Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification,...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Reports Results of Annual General Meeting
24 juin 2024 11h05 HE | Medigene AG
Shareholders approve all proposed resolutionsRe-election of two members of the Supervisory BoardReduction of share capital by consolidation of shares at a ratio of 2:1 approvedCreation of new...
22157.jpg
Global CAR-T Cell Therapy Market Report 2024: Detailed Coverage of the Approved CAR-T Products, including Regulatory Approvals, Pricing, Reimbursement and Degree of Market Penetration
24 juin 2024 10h00 HE | Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. ...
NurExone logo2.png
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
21 juin 2024 16h04 HE | NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
20 juin 2024 08h00 HE | Medigene AG
Planegg/Martinsried, June 20, 2024. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...